Related Experiment Video
Updated: Apr 28, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports
Sabino De Placido1, Pasquale Rescigno1, Piera Federico1
1Pasquale Rescigno, Piera Federico, Carlo Buonerba, Davide Bosso, Livio Puglia, Michela Izzo, Tania Policastro, Sabino De Placido, Giuseppe Di Lorenzo, Genitourinary Cancer Section, Medical Oncology, Department of Clinical Medicine, Federico II University, Napoli 80140, Italy.
Abstract:
Prostate cancer is the most common non-cutaneous malignancy for men. The skeleton is the most common metastatic site but, following an improvement in survival, metastases in uncommon sites are being found more frequently in clinical practice, especially brain metastases. Despite the new drugs now available for metastatic castration resistant prostate cancer, no clinical evidence exists about their effectiveness on brain metastases. We describe the clinical history of 3 patients treated with cabazitaxel plus whole brain radiotherapy. These case reports demonstrate that cabazitaxel is highly active and well tolerated in brain metastases.
Insights
Cabazitaxel shows significant activity and good tolerance for treating brain metastases in men with advanced prostate cancer. This combination therapy offers a new option for managing these challenging secondary tumors.
Area of Science:
- Oncology
- Neurology
- Prostate Cancer Research
Background:
- Prostate cancer is a leading malignancy in men, with skeletal metastases being common.
- Improved survival leads to increased detection of metastases in unusual sites, including the brain.
- Effectiveness of novel therapies on brain metastases in castration-resistant prostate cancer remains largely uncharacterized.
